Quest Diagnostics (DGX)
Market Price (9/2/2026): $236.22 | Market Cap: $26.2 BilInvestor Relations Sector: Health Care | Industry: Health Care Services
Quest Diagnostics (DGX)
Market Price (9/2/2026): $236.22Market Cap: $26.2 BilSector: Health CareIndustry: Health Care Services
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
Attractive yieldTotal YieldTotal Yield = Earnings Yield + Dividend Yield, Earnings Yield = Net Income / Market Cap Dividend Yield = Total Dividends / Market Cap is 5.4%, FCF Yield is 5.1% Attractive cash flow generationCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 16%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is 12% Low stock price volatilityVol 12M is 24% Megatrend and thematic driversMegatrends include Biotechnology & Genomics, Precision Medicine, and Digital Health & Telemedicine. Themes include Advanced Diagnostics, Show more. | Trading close to highsDist 52W High is -3.6%, Dist 3Y High is -3.6% | Key risksDGX key risks include [1] intense competition from technological advancements and the internalization of testing services, Show more. |
| Attractive yieldTotal YieldTotal Yield = Earnings Yield + Dividend Yield, Earnings Yield = Net Income / Market Cap Dividend Yield = Total Dividends / Market Cap is 5.4%, FCF Yield is 5.1% |
| Attractive cash flow generationCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 16%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is 12% |
| Low stock price volatilityVol 12M is 24% |
| Megatrend and thematic driversMegatrends include Biotechnology & Genomics, Precision Medicine, and Digital Health & Telemedicine. Themes include Advanced Diagnostics, Show more. |
| Trading close to highsDist 52W High is -3.6%, Dist 3Y High is -3.6% |
| Key risksDGX key risks include [1] intense competition from technological advancements and the internalization of testing services, Show more. |
Qualitative Assessment
AI Analysis | Feedback
Quest Diagnostics (DGX) stock has gained about 20% since 5/31/2026 because of the following key factors:
1. Strong Fiscal Second Quarter 2026 Financial Results and Raised Full-Year Guidance.
Quest Diagnostics reported robust performance for its fiscal second quarter 2026 (ended June 30, 2026) on July 23, 2026, significantly surpassing analyst expectations. The company announced revenues of $3.04 billion, an increase of 10.2% year-over-year, largely driven by 10.0% organic revenue growth. This exceeded analysts' consensus estimate of $2.97 billion. Additionally, adjusted diluted earnings per share (EPS) rose 19.1% year-over-year to $3.12, beating the consensus estimate of $2.82 by $0.30, or 10.6%. Following these strong results, Quest Diagnostics raised its full-year 2026 revenue guidance to a range of $11.95 billion to $12.05 billion and adjusted diluted EPS guidance to between $11.05 and $11.25. This updated outlook, reflecting confidence in sustained demand across physician, hospital, and consumer channels, fueled an over 11% surge in the company's shares in premarket trading on the day of the announcement.
2. Expansion of Strategic Collaborations and Growth in Advanced Diagnostics.
The company's strategic initiatives and focus on advanced diagnostic testing contributed significantly to its stock appreciation. In fiscal Q2 2026, Quest Diagnostics continued to advance its Co-Lab Solutions and a joint venture laboratory with Corewell Health in Michigan, along with developing new kidney care capabilities through its collaboration with Fresenius Medical Care in the United States. Furthermore, Quest Diagnostics experienced double-digit revenue growth in several key areas of Advanced Diagnostics, including its Quest AD-Detect® blood tests for Alzheimer's disease and advanced cardiometabolic and endocrine tests. Subsequent to the fiscal Q2 2026 earnings, in late August 2026, the company announced it would offer the FDA-cleared Roche pTau217 blood test for Alzheimer's disease pathology and launched a new multi-biomarker AD-Detect® lab-developed blood test. It also formalized a multi-year agreement with Renalytix PLC to offer kidneyintelX.dkd testing across its national network and introduced the Humanity Biological Age wellness offering, broadening its service portfolio and market reach.
Show more
Quest Diagnostics (DGX) stock has gained about 20% since 5/31/2026 because of the following key factors:
1. Strong Fiscal Second Quarter 2026 Financial Results and Raised Full-Year Guidance.
Quest Diagnostics reported robust performance for its fiscal second quarter 2026 (ended June 30, 2026) on July 23, 2026, significantly surpassing analyst expectations. The company announced revenues of $3.04 billion, an increase of 10.2% year-over-year, largely driven by 10.0% organic revenue growth. This exceeded analysts' consensus estimate of $2.97 billion. Additionally, adjusted diluted earnings per share (EPS) rose 19.1% year-over-year to $3.12, beating the consensus estimate of $2.82 by $0.30, or 10.6%. Following these strong results, Quest Diagnostics raised its full-year 2026 revenue guidance to a range of $11.95 billion to $12.05 billion and adjusted diluted EPS guidance to between $11.05 and $11.25. This updated outlook, reflecting confidence in sustained demand across physician, hospital, and consumer channels, fueled an over 11% surge in the company's shares in premarket trading on the day of the announcement.
2. Expansion of Strategic Collaborations and Growth in Advanced Diagnostics.
The company's strategic initiatives and focus on advanced diagnostic testing contributed significantly to its stock appreciation. In fiscal Q2 2026, Quest Diagnostics continued to advance its Co-Lab Solutions and a joint venture laboratory with Corewell Health in Michigan, along with developing new kidney care capabilities through its collaboration with Fresenius Medical Care in the United States. Furthermore, Quest Diagnostics experienced double-digit revenue growth in several key areas of Advanced Diagnostics, including its Quest AD-Detect® blood tests for Alzheimer's disease and advanced cardiometabolic and endocrine tests. Subsequent to the fiscal Q2 2026 earnings, in late August 2026, the company announced it would offer the FDA-cleared Roche pTau217 blood test for Alzheimer's disease pathology and launched a new multi-biomarker AD-Detect® lab-developed blood test. It also formalized a multi-year agreement with Renalytix PLC to offer kidneyintelX.dkd testing across its national network and introduced the Humanity Biological Age wellness offering, broadening its service portfolio and market reach.
3. Increased Requisition Volume Reflecting Robust Demand.
A core driver of the increased revenues was a substantial rise in testing demand. Quest Diagnostics reported a 13.1% year-over-year increase in total requisition volume for fiscal Q2 2026, with organic volume growth at 13.0%. This strong volume expansion demonstrates robust underlying demand for the company's diagnostic services across its various channels—physician, hospital, and consumer—underscoring the effectiveness of its strategy to connect providers and patients with innovative testing and actionable insights. This growth, while leading to a slight decline of 2.8% in revenue per requisition due to business mix from large hospital collaborations, still powered double-digit revenue expansion for the Diagnostic Information Services segment.
Show less
Stock Movement Drivers
Fundamental Drivers
The 21.7% change in DGX stock from 5/31/2026 to 9/1/2026 was primarily driven by a 18.4% change in the company's P/E Multiple.| (LTM values as of) | 5312026 | 9012026 | Change |
|---|---|---|---|
| Stock Price ($) | 194.11 | 236.22 | 21.7% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 11,278 | 11,560 | 2.5% |
| Net Income Margin (%) | 9.1% | 9.2% | 1.2% |
| P/E Multiple | 20.9 | 24.7 | 18.4% |
| Shares Outstanding (Mil) | 110 | 111 | -0.9% |
| Cumulative Contribution | 21.7% |
Market Drivers
5/31/2026 to 9/1/2026| Return | Correlation | |
|---|---|---|
| DGX | 21.7% | |
| Market (SPY) | 0.7% | -23.2% |
| Sector (XLV) | 14.9% | 50.5% |
Fundamental Drivers
The 12.4% change in DGX stock from 2/28/2026 to 9/1/2026 was primarily driven by a 7.9% change in the company's P/E Multiple.| (LTM values as of) | 2282026 | 9012026 | Change |
|---|---|---|---|
| Stock Price ($) | 210.14 | 236.22 | 12.4% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 11,035 | 11,560 | 4.8% |
| Net Income Margin (%) | 9.0% | 9.2% | 2.2% |
| P/E Multiple | 22.9 | 24.7 | 7.9% |
| Shares Outstanding (Mil) | 108 | 111 | -2.7% |
| Cumulative Contribution | 12.4% |
Market Drivers
2/28/2026 to 9/1/2026| Return | Correlation | |
|---|---|---|
| DGX | 12.4% | |
| Market (SPY) | 11.4% | -7.1% |
| Sector (XLV) | 7.6% | 49.9% |
Fundamental Drivers
The 32.3% change in DGX stock from 8/31/2025 to 9/1/2026 was primarily driven by a 17.3% change in the company's P/E Multiple.| (LTM values as of) | 8312025 | 9012026 | Change |
|---|---|---|---|
| Stock Price ($) | 178.51 | 236.22 | 32.3% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 10,522 | 11,560 | 9.9% |
| Net Income Margin (%) | 9.0% | 9.2% | 1.8% |
| P/E Multiple | 21.0 | 24.7 | 17.3% |
| Shares Outstanding (Mil) | 112 | 111 | 0.9% |
| Cumulative Contribution | 32.3% |
Market Drivers
8/31/2025 to 9/1/2026| Return | Correlation | |
|---|---|---|
| DGX | 32.3% | |
| Market (SPY) | 19.1% | -7.5% |
| Sector (XLV) | 26.5% | 35.4% |
Fundamental Drivers
The 90.5% change in DGX stock from 8/31/2023 to 9/1/2026 was primarily driven by a 41.2% change in the company's P/E Multiple.| (LTM values as of) | 8312023 | 9012026 | Change |
|---|---|---|---|
| Stock Price ($) | 123.99 | 236.22 | 90.5% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 9,488 | 11,560 | 21.8% |
| Net Income Margin (%) | 8.4% | 9.2% | 9.8% |
| P/E Multiple | 17.5 | 24.7 | 41.2% |
| Shares Outstanding (Mil) | 112 | 111 | 0.9% |
| Cumulative Contribution | 90.5% |
Market Drivers
8/31/2023 to 9/1/2026| Return | Correlation | |
|---|---|---|
| DGX | 90.5% | |
| Market (SPY) | 75.1% | 11.7% |
| Sector (XLV) | 34.9% | 41.1% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| DGX Return | 48% | -8% | -10% | 12% | 17% | 40% | 125% |
| Peers Return | 25% | -29% | 23% | 3% | 20% | 30% | 76% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 12% | 105% |
Monthly Win Rates [3] | |||||||
| DGX Win Rate | 75% | 50% | 42% | 58% | 58% | 75% | |
| Peers Win Rate | 58% | 38% | 50% | 50% | 55% | 68% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 50% | |
Max Drawdowns [4] | |||||||
| DGX Max Drawdown | -14% | -29% | -22% | -12% | -10% | -12% | |
| Peers Max Drawdown | -23% | -45% | -31% | -26% | -31% | -27% | |
| S&P 500 Max Drawdown | -5% | -25% | -10% | -8% | -19% | -9% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: HCA, LH, DVA, NEO, CVS. See DGX Returns vs. Peers.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 9/1/2026 (YTD)
How Low Can It Go
| Event | DGX | S&P 500 |
|---|---|---|
| Summer-Fall 2023 Five Percent Yield Shock | ||
| % Loss | -16.6% | -9.5% |
| % Gain to Breakeven | 19.9% | 10.5% |
| Time to Breakeven | 228 days | 24 days |
| 2023 SVB Regional Banking Crisis | ||
| % Loss | -10.3% | -6.7% |
| % Gain to Breakeven | 11.5% | 7.1% |
| Time to Breakeven | 70 days | 31 days |
| 2022 Inflation Shock & Fed Tightening | ||
| % Loss | -24.9% | -24.5% |
| % Gain to Breakeven | 33.1% | 32.4% |
| Time to Breakeven | 708 days | 427 days |
| 2020 COVID-19 Crash | ||
| % Loss | -35.4% | -33.7% |
| % Gain to Breakeven | 54.7% | 50.9% |
| Time to Breakeven | 24 days | 140 days |
| Q4 2018 Fed Policy Error / Growth Scare | ||
| % Loss | -24.6% | -19.2% |
| % Gain to Breakeven | 32.6% | 23.8% |
| Time to Breakeven | 256 days | 105 days |
| 2015-2016 China Devaluation / Global Growth Scare | ||
| % Loss | -17.8% | -12.2% |
| % Gain to Breakeven | 21.6% | 13.9% |
| Time to Breakeven | 191 days | 62 days |
In The Past
Quest Diagnostics's stock fell -6.5% during the 2025 US Tariff Shock. Such a loss loss requires a 7.0% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
| Event | DGX | S&P 500 |
|---|---|---|
| 2022 Inflation Shock & Fed Tightening | ||
| % Loss | -24.9% | -24.5% |
| % Gain to Breakeven | 33.1% | 32.4% |
| Time to Breakeven | 708 days | 427 days |
| 2020 COVID-19 Crash | ||
| % Loss | -35.4% | -33.7% |
| % Gain to Breakeven | 54.7% | 50.9% |
| Time to Breakeven | 24 days | 140 days |
| Q4 2018 Fed Policy Error / Growth Scare | ||
| % Loss | -24.6% | -19.2% |
| % Gain to Breakeven | 32.6% | 23.8% |
| Time to Breakeven | 256 days | 105 days |
| 2010 Eurozone Sovereign Debt Crisis / Flash Crash | ||
| % Loss | -22.2% | -15.4% |
| % Gain to Breakeven | 28.6% | 18.2% |
| Time to Breakeven | 188 days | 125 days |
| 2008-2009 Global Financial Crisis | ||
| % Loss | -24.2% | -53.4% |
| % Gain to Breakeven | 31.9% | 114.4% |
| Time to Breakeven | 186 days | 1085 days |
In The Past
Quest Diagnostics's stock fell -6.5% during the 2025 US Tariff Shock. Such a loss loss requires a 7.0% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About Quest Diagnostics (DGX)
Quest Diagnostics Incorporated (DGX) is a prominent provider of diagnostic testing, information, and services, operating across the United States and internationally. The company's fundamental role in healthcare involves developing and delivering critical diagnostic information that supports patient care and health management.
The company's core offerings include a comprehensive suite of diagnostic information services. These range from routine and non-routine testing to advanced clinical testing and anatomic pathology, provided under its primary Quest Diagnostics brand, as well as specialized brands like AmeriPath and Dermpath Diagnostics. Beyond clinical diagnostics, DGX also offers risk assessment services for the life insurance industry and robust information technology solutions designed for healthcare organizations and clinicians.
Quest Diagnostics serves a diverse client base, including individual patients, clinicians, hospitals, independent delivery networks, health plans, employers, and accountable care organizations. The company reaches these markets through an extensive network of laboratories, patient service centers, phlebotomists in physician offices, and mobile health professionals, ensuring broad accessibility to its diagnostic capabilities.
AI Analysis | Feedback
Here are 1-3 brief analogies to describe Quest Diagnostics:
- Quest Diagnostics is like a national **CVS or Walgreens for medical lab tests**.
- It's the **FedEx or UPS for collecting and analyzing medical samples**.
- Think of it as the **Amazon for diagnostic health services**.
AI Analysis | Feedback
- Clinical Diagnostic Testing: Provides a comprehensive range of medical tests, including routine, advanced clinical, and anatomic pathology, to diagnose and monitor health conditions.
- Risk Assessment Services: Offers specialized services, primarily for the life insurance industry, to evaluate health risks.
- Healthcare IT Solutions: Develops and delivers robust information technology solutions for healthcare organizations and clinicians.
AI Analysis | Feedback
Quest Diagnostics (DGX) primarily sells its diagnostic testing, information, and services to other companies and organizations, although the ultimate recipients of many services are individual patients. The provided background information describes the types of organizations it serves, but does not specify individual customer company names or their public symbols.
Based on the description, Quest Diagnostics' major categories of organizational customers include:
- Healthcare Providers and Systems: This category encompasses entities such as hospitals, independent delivery networks, accountable care organizations, and clinicians (who often represent medical practices or healthcare facilities).
- Health Plans: These are health insurance companies that contract with Quest Diagnostics to provide services to their members.
- Employers: Companies that contract for services, potentially including employee wellness programs, occupational health services, and drug testing.
- Direct Contract Entities: Various other organizations that engage in direct contracts with Quest Diagnostics for its services.
AI Analysis | Feedback
- Thermo Fisher Scientific Inc. (NYSE: TMO)
- Roche Holding AG (SWX: ROG)
- Siemens Healthineers AG (ETR: SHL)
- Abbott Laboratories (NYSE: ABT)
- Danaher Corporation (NYSE: DHR)
AI Analysis | Feedback
Jim Davis, Chairman, CEO and President
Jim Davis assumed the role of CEO and President of Quest Diagnostics on November 1, 2022, and became Chairman on April 1, 2023. He joined Quest in April 2013, initially serving as Senior Vice President, Diagnostic Services, then Senior Vice President, Operations. Before joining Quest, he was CEO of InSightec, Inc., a medical device company. Prior to that, he held senior management positions in General Electric's aviation and healthcare businesses, including leading GE's MRI business for five years, and led strategic and operating initiatives for clients of McKinsey & Company, Inc.
Sam Samad, Executive Vice President and Chief Financial Officer
Sam Samad joined Quest Diagnostics in July 2022. Prior to Quest, he served as Chief Financial Officer at Illumina, Inc. since 2017, where he was responsible for the company's finance, accounting, investor relations, internal audit, and treasury functions. Before Illumina, Samad held several senior leadership positions at Cardinal Health, including Senior Vice President and Corporate Treasurer, and Senior Vice President and CFO for Cardinal Health's $85 billion pharmaceutical segment. He also spent 13 years at Eli Lilly and Company in various sales and finance roles, both domestically and internationally, including as CFO of their Canada affiliate.
Catherine Doherty, Executive Vice President, Regional Businesses
Catherine Doherty joined Quest Diagnostics in 1990. She oversees regional and enterprise operations, as well as the commercial organization, marketing, and consumer-initiated testing. She is also responsible for driving operational excellence, and co-chairs the company's Inclusion and Diversity Council, and is Executive Sponsor of Quest's Women in Leadership Employee Business Network. Her previous roles at Quest include Senior Vice President, Group Executive – Clinical Franchise Solutions & Marketing; Senior Vice President, Physician Services Business; Vice President, Hospital Services; and Vice President, Office of the Chairman. She is a certified public accountant.
Michael E. Prevoznik, Senior Vice President & General Counsel
Michael E. Prevoznik joined Quest Diagnostics in 1999 through the acquisition of SmithKline Beecham Clinical Laboratories (SBCL). He is responsible for legal, regulatory compliance, security, and government affairs. Prior to joining Quest, he served as Chief Legal Compliance Officer for SBCL starting in 1994, then Vice President and Chief Legal Compliance Officer for SmithKline Beecham Healthcare Services, and Vice President, Compliance for SmithKline Beecham, where he developed and led the company's global compliance activities. Before joining SmithKline Beecham, Prevoznik was an Associate with Dechert Price & Rhoads, specializing in healthcare and general corporate law.
Benjamin Beauvalot, Senior Vice President, Chief Strategy and M&A Officer
Benjamin Beauvalot joined Quest Diagnostics in February 2026. He brings over two decades of experience in strategy, mergers and acquisitions (M&A), and transformation. Previously, he held significant positions in strategy and M&A at Danaher Corporation, including Vice President and head of business development and strategy in the biotechnology and genomics sectors. His background also includes roles as Vice President of strategy and corporate development, and later Vice President of global business operations at Patheon, as well as Vice President of strategy for Banner Life Sciences. He is responsible for developing Quest Diagnostics' growth strategy and leading mergers and acquisitions, strategic partnerships, and integrations.
AI Analysis | Feedback
The key risks for Quest Diagnostics (DGX) primarily revolve around its crucial role in handling sensitive patient data, the highly regulated healthcare environment, and the evolving competitive and technological landscape.
1. Cybersecurity and Data Breaches
Quest Diagnostics faces a significant and ongoing risk from cybersecurity threats and potential data breaches, particularly given the vast amount of sensitive patient information it handles. Past incidents, such as the 2019 data breach involving a third-party vendor, American Medical Collection Agency (AMCA), exposed personal information, including names, dates of birth, Social Security numbers, credit card information, and medical data, for millions of patients. This type of breach not only leads to significant financial and reputational damage but also raises concerns about vendor risk management and compliance with regulations like HIPAA. The healthcare sector remains a prime target for cyberattacks, making robust data security and vendor oversight critical for Quest Diagnostics.
2. Regulatory and Reimbursement Pressures
As a prominent player in the healthcare industry, Quest Diagnostics is highly susceptible to stringent regulatory oversight and changes in reimbursement policies. The company has faced legal and financial consequences for non-compliance, exemplified by a nearly $5 million settlement in California in 2024 for the unlawful disposal of hazardous waste, medical waste, and protected patient information. Beyond environmental and data privacy regulations, Quest Diagnostics also faces "payor pressure" from entities like Medicare, which can directly impact the reimbursement rates for its diagnostic testing services and, consequently, its revenue and profit margins.
3. Competition and Evolving Healthcare Landscape
Quest Diagnostics operates in a highly competitive and dynamic diagnostic testing industry. Its primary rival is LabCorp, but competition also comes from hospital-affiliated laboratories, physician-office laboratories, and emerging consumer-initiated testing providers. This intense competition puts continuous pressure on Quest to innovate and adapt. Furthermore, technological advancements in diagnostic testing and the increasing trend of hospitals internalizing clinical laboratory testing, including some non-routine and advanced tests, could lead to reduced demand for Quest's services. The evolving healthcare models, including changes in healthcare plans and public health emergencies, can also impact testing volumes and revenue for the company.
AI Analysis | Feedback
One clear emerging threat for Quest Diagnostics (DGX) is the rise of direct-to-consumer (DTC) at-home diagnostic testing services. These services enable individuals to collect samples (e.g., saliva, blood via finger prick) at home and mail them to a lab for analysis, bypassing the need to visit Quest's patient service centers or phlebotomists. As these services expand in scope, accuracy, and clinical acceptance, they offer a more convenient and accessible alternative for various routine and wellness-related tests, potentially reducing demand for Quest's traditional sample collection and processing infrastructure.
Another clear emerging threat is the rapid advancement and proliferation of point-of-care testing (POCT) technologies. As POCT devices become more sophisticated, accurate, and capable of performing a wider range of complex tests, diagnostics can increasingly be conducted in physician offices, clinics, pharmacies, or even remotely, without sending samples to large central laboratories like Quest. This decentralization of testing can reduce the reliance on Quest's extensive network of collection sites and central lab infrastructure by allowing for immediate or near-immediate results where the patient is located.
AI Analysis | Feedback
Quest Diagnostics (symbol: DGX) operates within several significant addressable markets for its diagnostic testing, information, and services. The key markets and their estimated sizes are detailed below, with regions specified where available:
- Diagnostic Testing (Routine, Non-Routine, and Advanced Clinical Testing):
- The global diagnostic testing market was estimated at approximately USD 207.96 billion in 2025 and is projected to reach around USD 281.56 billion by 2035.
- North America held a substantial share of the global diagnostic testing market, accounting for 42.5% in 2024. The U.S. alone captured 79% of the North American market in 2024.
- The global clinical laboratory services market was valued at USD 291.01 billion in 2025 and is projected to grow to USD 545.79 billion by 2034. North America dominated this market with a 42.56% share in 2025.
- The U.S. clinical diagnostics market generated revenues of USD 44,690.6 million in 2024 and is expected to reach USD 63,081.8 million by 2030.
- Anatomic Pathology Testing:
- The global anatomic pathology market was estimated at USD 38.55 billion in 2025 and is predicted to increase to approximately USD 86.97 billion by 2035.
- North America held the largest share of the global anatomic pathology market, accounting for 45% in 2025.
- Risk Assessment Services for the Life Insurance Industry:
- The broader global insurance market was valued at USD 9.0 trillion in 2023 and is projected to reach USD 28.5 trillion by 2032.
- The global insurance analytics market, which supports risk assessment, was estimated at USD 19.3 billion in 2025 and is projected to grow to USD 54.54 billion by 2034.
- North America dominated the global insurance analytics market with a 40.40% share in 2025. The U.S. market specifically is projected to reach USD 5.19 billion by 2026.
- Healthcare Information Technology (IT) Solutions:
- The total global healthcare IT industry market size is projected to reach USD 279.5 billion in 2025. Another estimate places the global market at USD 354.04 billion in 2025, growing to USD 1380.51 billion by 2034.
- The U.S. healthcare IT market size is estimated at USD 176.6 billion, accounting for 63% of the global healthcare IT industry spend. Other projections for the U.S. market indicate a growth from USD 182.09 billion in 2025 to USD 566.48 billion by 2034.
AI Analysis | Feedback
Quest Diagnostics (DGX) anticipates several key drivers to fuel future revenue growth over the next 2-3 years:
-
Growth in Advanced Diagnostics: The company expects to achieve double-digit growth in advanced diagnostics across various clinical areas, including molecular genomics, oncology (notably minimal residual disease testing like Haystack Oncology), cardiometabolic, prenatal and hereditary genetics, neurology, brain health, autoimmune, and women's health.
-
Strategic Partnerships and Acquisitions: Quest Diagnostics plans to drive growth through strategic partnerships, such as joint ventures with health systems like Corewell Health for lab services, and through accretive acquisitions, including hospital outreach purchases and smaller independent laboratories. Recent examples include acquiring select dialysis testing assets.
-
Expanded Health Plan Network Access and Physician Channel Growth: Revenue growth is expected from increased market access with health plans, including successful negotiations for strategic health plan renewals and growth from value-based contracts and Medicare Advantage plans. The company also aims to grow in the physician channel by delivering comprehensive diagnostic innovation, extending geographic reach, and becoming a preferred partner for large enterprise customers.
-
Expansion of Hospital Lab Services: Quest Diagnostics intends to grow by serving hospitals through scaled and specialized reference testing, as well as by extending its collaborative lab solutions, which involve managing hospital laboratories, supply chains, and workforces.
-
Consumer-Initiated Testing and Digital Partnerships: The company is focused on driving revenue growth through its consumer-facing platform, questhealth.com, and by forming partnerships with mobile health companies such as WHOOP and OURA Health, which are anticipated to bring additional volume and relevance to Quest's consumer health offerings.
AI Analysis | Feedback
Share Repurchases
- In February 2026, Quest Diagnostics' Board of Directors authorized an additional $1 billion for its common stock repurchase program.
- As of December 31, 2025, approximately $0.4 billion remained available under the company's existing share repurchase program.
Share Issuance
- As of February 2, 2026, there were approximately 109.9 million shares of common stock outstanding.
- As of January 31, 2025, there were approximately 111 million shares of common stock outstanding.
- In March 2026, an SVP was awarded 5,682 shares in settlement of a performance stock award, with 2,326 shares withheld for taxes.
Outbound Investments
- Quest Diagnostics expanded through acquisitions in 2025, including LifeLabs in Canada and Spectra Laboratories assets.
- In August 2025, the company completed the acquisition of select clinical testing assets from Fresenius Medical Care's wholly owned Spectra Laboratories.
- In October 2024, Quest Diagnostics completed the acquisition of select laboratory assets from OhioHealth to broaden access to laboratory services in Ohio.
- Strategic collaborations include a laboratory-services joint venture with Corewell Health in Michigan, which involves plans to open a new laboratory in 2027.
Capital Expenditures
- Capital expenditures for the full year 2025 were $527 million, and for 2024 were $425 million.
- The company's guidance for full-year 2025 anticipated approximately $500 million in capital expenditures.
- Capital investments are primarily focused on modernizing IT systems (Project Nova), fortifying clinical infrastructure, digital capabilities, lab automation, and AI initiatives.
Peer Outperformance in Health Care Services
| Industry | Names | 1Y med | 3Y med | 5Y med | Top 3 by 5Y |
|---|---|---|---|---|---|
| Health Care Distributors | 7 | 14.4% | 94.0% | 140.0% | CAH 398% · MCK 349% · COR 179% |
| Managed Health Care | 8 | 31.6% | 1.1% | 1.5% | OSCR 63% · HQY 47% · ELV 13% |
| Health Care Services ← | 20 | 16.6% | 45.6% | -4.3% | HIMS 241% · RDNT 141% · DGX 68% |
| Health Care Equipment | 51 | -4.3% | -7.9% | -20.5% | POCI 10500% · UFPT 322% · GKOS 195% |
| Health Care Facilities | 24 | 6.2% | -4.7% | -20.7% | THC 250% · NHC 239% · ENSG 110% |
| Health Care Supplies | 12 | 29.8% | -17.0% | -37.5% | LNTH 272% · HAE 55% · MMSI 24% |
| Pharmaceuticals | 63 | -0.7% | 2.5% | -37.6% | LQDA 2281% · INDV 1175% · ETON 1040% |
| Life Sciences Tools & Services | 109 | -2.0% | -32.5% | -73.1% | SNWV 1778% · MEDP 201% · AXGN 182% |
| Biotechnology | 363 | 10.1% | -28.0% | -77.0% | BRTX 99050% · DNTH 1513% · CELZ 1471% |
| Health Care Technology | 20 | -26.2% | -59.5% | -78.0% | SPOK 72% · HSTM -1% · VEEV -12% |
Latest Trefis Analyses
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 206.18 |
| Mkt Cap | 26.5 |
| Rev LTM | 14,179 |
| Op Inc LTM | 1,863 |
| FCF LTM | 1,479 |
| FCF 3Y Avg | 1,269 |
| CFO LTM | 2,048 |
| CFO 3Y Avg | 1,782 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 7.3% |
| Rev Chg 3Y Avg | 7.0% |
| Rev Chg Q | 8.0% |
| QoQ Delta Rev Chg LTM | 1.9% |
| Op Inc Chg LTM | 21.3% |
| Op Inc Chg 3Y Avg | 10.4% |
| Op Mgn LTM | 12.7% |
| Op Mgn 3Y Avg | 11.9% |
| QoQ Delta Op Mgn LTM | 0.2% |
| CFO/Rev LTM | 12.8% |
| CFO/Rev 3Y Avg | 13.2% |
| FCF/Rev LTM | 7.9% |
| FCF/Rev 3Y Avg | 8.2% |
Valuation
| Median | |
|---|---|
| Name | |
| Mkt Cap | 26.5 |
| P/S | 1.5 |
| P/Op Inc | 8.2 |
| P/EBIT | 10.8 |
| P/E | 19.1 |
| P/CFO | 11.1 |
| Total Yield | 6.0% |
| Dividend Yield | 0.8% |
| FCF Yield 3Y Avg | 6.4% |
| D/E | 0.4 |
| Net D/E | 0.4 |
Returns
| Median | |
|---|---|
| Name | |
| 1M Rtn | 2.1% |
| 3M Rtn | 17.8% |
| 6M Rtn | 16.0% |
| 12M Rtn | 30.1% |
| 3Y Rtn | 64.9% |
| 1M Excs Rtn | 1.4% |
| 3M Excs Rtn | 17.5% |
| 6M Excs Rtn | 4.1% |
| 12M Excs Rtn | 12.0% |
| 3Y Excs Rtn | -12.5% |
Comparison Analyses
Segment Financials
Revenue by Segment| $ Mil | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Diagnostic Information Services (DIS) | 10,785 | 9,614 | 8,976 | 9,609 | 10,494 |
| Diagnostic Solutions (DS) | 250 | 258 | 276 | 274 | |
| All other operating segments | 294 | ||||
| Total | 11,035 | 9,872 | 9,252 | 9,883 | 10,788 |
| $ Mil | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Diagnostic Information Services (DIS) | 1,829 | 1,630 | 1,547 | 1,704 | 2,646 |
| Diagnostic Solutions (DS) | 32 | 33 | 34 | 20 | |
| General corporate activities | -305 | -317 | -319 | -296 | -294 |
| All other operating segments | 29 | ||||
| Total | 1,556 | 1,346 | 1,262 | 1,428 | 2,381 |
Price Behavior
| Market Price | $236.22 | |
| Market Cap ($ Bil) | 26.2 | |
| First Trading Date | 12/26/1996 | |
| Distance from 52W High | -3.6% | |
| 50 Days | 200 Days | |
| DMA Price | $225.15 | $199.12 |
| DMA Trend | up | up |
| Distance from DMA | 4.9% | 18.6% |
| 3M | 1YR | |
| Volatility | 26.2% | 23.7% |
| Downside Capture | -93.61 | -33.86 |
| Upside Capture | 7.21 | 5.74 |
| Correlation (SPY) | -24.9% | -7.4% |
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 0.10 | -0.70 | -0.49 | -0.14 | -0.14 | 0.17 |
| Up Beta | -0.37 | -0.56 | -0.26 | 0.01 | 0.01 | 0.21 |
| Down Beta | -0.13 | -2.22 | -0.65 | -0.32 | -0.23 | 0.12 |
| Up Capture | 54% | 11% | 3% | 3% | 4% | 8% |
| Bmk +ve Days | 10 | 21 | 32 | 68 | 138 | 427 |
| Stock +ve Days | 10 | 16 | 28 | 60 | 121 | 373 |
| Down Capture | 12% | -105% | -129% | -39% | -57% | 12% |
| Bmk -ve Days | 11 | 21 | 32 | 59 | 113 | 324 |
| Stock -ve Days | 11 | 26 | 36 | 67 | 130 | 376 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with DGX | |
|---|---|---|---|---|
| DGX | 32.5% | 23.7% | 1.12 | - |
| Sector ETF (XLV) | 26.7% | 16.0% | 1.29 | 35.3% |
| Equity (SPY) | 19.2% | 12.8% | 1.10 | -6.9% |
| Gold (GLD) | 24.8% | 29.2% | 0.76 | -1.3% |
| Commodities (DBC) | 44.0% | 20.4% | 1.67 | -14.1% |
| Real Estate (VNQ) | 8.5% | 13.7% | 0.35 | 34.0% |
| Bitcoin (BTCUSD) | -27.6% | 43.5% | -0.62 | -11.0% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with DGX | |
|---|---|---|---|---|
| DGX | 11.7% | 22.3% | 0.44 | - |
| Sector ETF (XLV) | 6.4% | 15.1% | 0.24 | 48.6% |
| Equity (SPY) | 12.7% | 17.2% | 0.56 | 26.5% |
| Gold (GLD) | 18.7% | 18.7% | 0.81 | 5.2% |
| Commodities (DBC) | 11.0% | 19.5% | 0.44 | -0.8% |
| Real Estate (VNQ) | 2.0% | 18.9% | -0.00 | 39.3% |
| Bitcoin (BTCUSD) | 10.5% | 52.6% | 0.38 | 7.8% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with DGX | |
|---|---|---|---|---|
| DGX | 13.0% | 24.0% | 0.51 | - |
| Sector ETF (XLV) | 10.5% | 16.7% | 0.51 | 52.2% |
| Equity (SPY) | 15.1% | 17.9% | 0.72 | 41.1% |
| Gold (GLD) | 12.0% | 16.3% | 0.60 | 6.5% |
| Commodities (DBC) | 7.9% | 18.1% | 0.35 | 7.1% |
| Real Estate (VNQ) | 4.9% | 20.7% | 0.20 | 43.3% |
| Bitcoin (BTCUSD) | 63.2% | 66.1% | 1.03 | 7.1% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Returns Analyses
Earnings Returns History
Updated 8/25/2026| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 7/23/2026 | 8.6% | 12.1% | 15.0% |
| 4/21/2026 | 4.4% | 0.2% | -3.0% |
| 2/10/2026 | 7.4% | 7.4% | 4.9% |
| 10/21/2025 | -3.0% | -5.3% | -2.7% |
| 7/22/2025 | 7.1% | 0.8% | 9.8% |
| 4/22/2025 | 6.8% | 9.2% | 10.1% |
| 1/30/2025 | 5.6% | 6.1% | 11.2% |
| 10/22/2024 | 6.9% | 5.8% | 9.4% |
| ... | |||
| SUMMARY STATS | |||
| # Positive | 14 | 13 | 15 |
| # Negative | 10 | 11 | 9 |
| Median Positive | 5.3% | 6.1% | 9.8% |
| Median Negative | -3.4% | -2.6% | -5.3% |
| Max Positive | 8.6% | 13.3% | 15.2% |
| Max Negative | -6.8% | -11.6% | -14.9% |
| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 7/23/2026 | 8.6% | 12.1% | 15.0% |
| 4/21/2026 | 4.4% | 0.2% | -3.0% |
| 2/10/2026 | 7.4% | 7.4% | 4.9% |
| 10/21/2025 | -3.0% | -5.3% | -2.7% |
| 7/22/2025 | 7.1% | 0.8% | 9.8% |
| 4/22/2025 | 6.8% | 9.2% | 10.1% |
| 1/30/2025 | 5.6% | 6.1% | 11.2% |
| 10/22/2024 | 6.9% | 5.8% | 9.4% |
| 7/23/2024 | -4.3% | -3.5% | 2.4% |
| 4/23/2024 | 5.1% | 7.2% | 10.2% |
| 2/1/2024 | -1.0% | -0.8% | -2.9% |
| 10/24/2023 | 1.8% | 6.6% | 10.6% |
| 7/26/2023 | -6.0% | -7.1% | -7.9% |
| 4/27/2023 | -4.0% | -7.0% | -9.6% |
| 2/2/2023 | -2.1% | -1.6% | -5.3% |
| 10/20/2022 | 6.3% | 13.3% | 15.2% |
| 7/21/2022 | -0.2% | -0.4% | 0.8% |
| 4/21/2022 | 2.3% | -0.7% | 1.2% |
| 1/12/2022 | -6.8% | -11.6% | -14.9% |
| 10/21/2021 | -1.0% | -2.0% | 0.7% |
| 7/22/2021 | 1.6% | 3.1% | 11.7% |
| 4/22/2021 | 2.8% | 1.3% | 1.1% |
| 2/4/2021 | -3.9% | -2.6% | -7.0% |
| 10/22/2020 | 2.9% | 1.7% | -0.0% |
| SUMMARY STATS | |||
| # Positive | 14 | 13 | 15 |
| # Negative | 10 | 11 | 9 |
| Median Positive | 5.3% | 6.1% | 9.8% |
| Median Negative | -3.4% | -2.6% | -5.3% |
| Max Positive | 8.6% | 13.3% | 15.2% |
| Max Negative | -6.8% | -11.6% | -14.9% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 06/30/2026 | 07/23/2026 | 10-Q |
| 03/31/2026 | 04/22/2026 | 10-Q |
| 12/31/2025 | 02/26/2026 | 10-K |
| 09/30/2025 | 10/21/2025 | 10-Q |
| 06/30/2025 | 07/23/2025 | 10-Q |
| 03/31/2025 | 04/23/2025 | 10-Q |
| 12/31/2024 | 02/20/2025 | 10-K |
| 09/30/2024 | 10/23/2024 | 10-Q |
| 06/30/2024 | 07/24/2024 | 10-Q |
| 03/31/2024 | 04/24/2024 | 10-Q |
| 12/31/2023 | 02/22/2024 | 10-K |
| 09/30/2023 | 10/25/2023 | 10-Q |
| 06/30/2023 | 07/27/2023 | 10-Q |
| 03/31/2023 | 04/28/2023 | 10-Q |
| 12/31/2022 | 02/21/2023 | 10-K |
| 09/30/2022 | 10/21/2022 | 10-Q |
| Report Date | Filing Date | Filing |
|---|---|---|
| 06/30/2026 | 07/23/2026 | 10-Q |
| 03/31/2026 | 04/22/2026 | 10-Q |
| 12/31/2025 | 02/26/2026 | 10-K |
| 09/30/2025 | 10/21/2025 | 10-Q |
| 06/30/2025 | 07/23/2025 | 10-Q |
| 03/31/2025 | 04/23/2025 | 10-Q |
| 12/31/2024 | 02/20/2025 | 10-K |
| 09/30/2024 | 10/23/2024 | 10-Q |
| 06/30/2024 | 07/24/2024 | 10-Q |
| 03/31/2024 | 04/24/2024 | 10-Q |
| 12/31/2023 | 02/22/2024 | 10-K |
| 09/30/2023 | 10/25/2023 | 10-Q |
| 06/30/2023 | 07/27/2023 | 10-Q |
| 03/31/2023 | 04/28/2023 | 10-Q |
| 12/31/2022 | 02/21/2023 | 10-K |
| 09/30/2022 | 10/21/2022 | 10-Q |
| 06/30/2022 | 07/22/2022 | 10-Q |
| 03/31/2022 | 04/22/2022 | 10-Q |
| 12/31/2021 | 02/28/2022 | 10-K |
| 09/30/2021 | 10/22/2021 | 10-Q |
| 06/30/2021 | 07/23/2021 | 10-Q |
| 03/31/2021 | 04/23/2021 | 10-Q |
| 12/31/2020 | 02/22/2021 | 10-K |
| 09/30/2020 | 10/23/2020 | 10-Q |
| 06/30/2020 | 07/24/2020 | 10-Q |
| 03/31/2020 | 05/04/2020 | 10-Q |
| 12/31/2019 | 02/20/2020 | 10-K |
| 09/30/2019 | 10/23/2019 | 10-Q |
Recent Forward Guidance
Updated 7/24/2026Latest: Q2 2026 Earnings Reported 7/23/2026
| Forward Guidance | Guidance Change | |||||||
|---|---|---|---|---|---|---|---|---|
| Metric | Source | Low | Mid | High | % Chg | % Delta | Change | Prior |
| 2026 Cash provided by operations | Reported | 1.80 Bil | 2.9% | Raised | Guidance: 1.75 Bil for 2026 | |||
| 2026 Revenue | Reported | 11.95 Bil | 12.00 Bil | 12.05 Bil | 1.4% | Raised | Guidance: 11.84 Bil for 2026 | |
| 2026 Revenue Growth | Reported | 8.3% | 8.75% | 9.2% | 1.4% | Raised | Guidance: 7.3% for 2026 | |
| 2026 Reported Diluted EPS | Reported | 9.97 | 10.1 | 10.2 | 4.0% | Raised | Guidance: 9.68 for 2026 | |
| 2026 Adjusted Diluted EPS | Reported | 11.1 | 11.2 | 11.2 | 3.9% | Raised | Guidance: 10.7 for 2026 | |
| 2026 Capital expenditures | Reported | 550.00 Mil | 0 | Affirmed | Guidance: 550.00 Mil for 2026 | |||
Prior: Q1 2026 Earnings Reported 4/21/2026
| Forward Guidance | Guidance Change | |||||||
|---|---|---|---|---|---|---|---|---|
| Metric | Source | Low | Mid | High | % Chg | % Delta | Change | Prior |
| 2026 Cash provided by operations | Reported | 1.75 Bil | 0 | Affirmed | Guidance: 1.75 Bil for 2026 | |||
| 2026 Net revenues | Reported | 11.78 Bil | 11.84 Bil | 11.90 Bil | 0.7% | Raised | Guidance: 11.76 Bil for 2026 | |
| 2026 Net revenues increase | Reported | 0.07 | 0.07 | 0.08 | 0.8% | Raised | Guidance: 0.07 for 2026 | |
| 2026 Reported diluted EPS | Reported | 9.58 | 9.68 | 9.78 | 1.4% | Raised | Guidance: 9.55 for 2026 | |
| 2026 Adjusted diluted EPS | Reported | 10.6 | 10.7 | 10.8 | 1.2% | Raised | Guidance: 10.6 for 2026 | |
| 2026 Capital expenditures | Reported | 550.00 Mil | 0 | Affirmed | Guidance: 550.00 Mil for 2026 | |||
Q4 2025 Earnings Reported 2/10/2026
| Forward Guidance | Guidance Change | |||||||
|---|---|---|---|---|---|---|---|---|
| Metric | Source | Low | Mid | High | % Chg | % Delta | Change | Prior |
| 2026 Cash provided by operations | Reported | 1.75 Bil | -2.8% | Lower New | Actual: 1.80 Bil for 2025 | |||
| 2026 Revenue | Reported | 11.70 Bil | 11.76 Bil | 11.82 Bil | 7.1% | Higher New | Actual: 10.98 Bil for 2025 | |
| 2026 Revenue Growth | Reported | 6.0% | 6.55% | 7.1% | -4.6% | Lower New | Actual: 11.2% for 2025 | |
| 2026 Reported Diluted EPS | Reported | 9.45 | 9.55 | 9.65 | 10.8% | Higher New | Actual: 8.62 for 2025 | |
| 2026 Adjusted Diluted EPS | Reported | 10.5 | 10.6 | 10.7 | 8.2% | Higher New | Actual: 9.8 for 2025 | |
| 2026 Capital expenditures | Reported | 550.00 Mil | 10.0% | Higher New | Actual: 500.00 Mil for 2025 | |||
Q3 2025 Earnings Reported 10/21/2025
| Forward Guidance | Guidance Change | |||||||
|---|---|---|---|---|---|---|---|---|
| Metric | Source | Low | Mid | High | % Chg | % Delta | Change | Prior |
| 2025 Cash provided by operations | Reported | 1.80 Bil | 16.1% | Raised | Guidance: 1.55 Bil for 2025 | |||
| 2025 Net revenues | Reported | 10.96 Bil | 10.98 Bil | 11.00 Bil | 1.1% | Raised | Guidance: 10.86 Bil for 2025 | |
| 2025 Net revenues increase | Reported | 0.11 | 0.11 | 0.11 | 1.2% | Raised | Guidance: 0.1 for 2025 | |
| 2025 Reported diluted EPS | Reported | 8.58 | 8.62 | 8.66 | -0.9% | Lowered | Guidance: 8.7 for 2025 | |
| 2025 Adjusted diluted EPS | Reported | 9.76 | 9.8 | 9.84 | 0.7% | Raised | Guidance: 9.73 for 2025 | |
| 2025 Capital expenditures | Reported | 500.00 Mil | 0.0% | Affirmed | Guidance: 500.00 Mil for 2025 | |||
| 2026 Co-Lab Solutions annual revenues | Reported | 1.00 Bil | ||||||
Insider Activity
Updated 8/31/2026| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Prevoznik, Michael E | SVP & General Counsel | Direct | Sell | 8312026 | 243.11 | 22,677 | 5,513,083 | 9,130,610 | Form |
| 2 | Delaney, Mark E | SVP & Chief Commercial Officer | Direct | Sell | 7292026 | 235.18 | 1,600 | 376,288 | 2,430,585 | Form |
| 3 | Kuppusamy, Karthik | SVP, Clinical Solutions | Direct | Sell | 6082026 | 200.00 | 8,147 | 1,629,400 | 2,702,000 | Form |
| 4 | Davis, J. E | CEO and President | Direct | Sell | 6022026 | 194.14 | 10,000 | 1,941,400 | 25,708,601 | Form |
| 5 | Doherty, Catherine T | EVP, Regional Businesses | Direct | Sell | 3062026 | 206.21 | 5,558 | 1,146,115 | 13,841,228 | Form |
| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Prevoznik, Michael E | SVP & General Counsel | Direct | Sell | 8312026 | 243.11 | 22,677 | 5,513,083 | 9,130,610 | Form |
| 2 | Delaney, Mark E | SVP & Chief Commercial Officer | Direct | Sell | 7292026 | 235.18 | 1,600 | 376,288 | 2,430,585 | Form |
| 3 | Kuppusamy, Karthik | SVP, Clinical Solutions | Direct | Sell | 6082026 | 200.00 | 8,147 | 1,629,400 | 2,702,000 | Form |
| 4 | Davis, J. E | CEO and President | Direct | Sell | 6022026 | 194.14 | 10,000 | 1,941,400 | 25,708,601 | Form |
| 5 | Doherty, Catherine T | EVP, Regional Businesses | Direct | Sell | 3062026 | 206.21 | 5,558 | 1,146,115 | 13,841,228 | Form |
| 6 | Prevoznik, Michael E | SVP & General Counsel | Direct | Sell | 3062026 | 206.21 | 3,878 | 799,682 | 7,744,629 | Form |
| 7 | Plewman, Patrick | SVP for Diagnostic Services | Direct | Sell | 3062026 | 206.21 | 2,855 | 588,730 | 3,133,980 | Form |
| 8 | Kuppusamy, Karthik | SVP, Clinical Solutions | Direct | Sell | 3062026 | 204.86 | 2,628 | 538,372 | 2,753,523 | Form |
| 9 | Doherty, Catherine T | EVP, Regional Businesses | Direct | Sell | 3042026 | 207.73 | 632 | 131,285 | 13,943,253 | Form |
| 10 | Prevoznik, Michael E | SVP & General Counsel | Direct | Sell | 3042026 | 207.73 | 526 | 109,266 | 7,801,716 | Form |
| 11 | Plewman, Patrick | SVP for Diagnostic Services | Direct | Sell | 3042026 | 207.73 | 410 | 85,169 | 3,157,081 | Form |
| 12 | Davis, J. E | CEO and President | Direct | Sell | 3042026 | 212.52 | 10,000 | 2,125,200 | 24,904,156 | Form |
| 13 | Plewman, Patrick | SVP for Diagnostic Services | Direct | Sell | 2202026 | 204.83 | 958 | 196,227 | 3,244,098 | Form |
| 14 | Prevoznik, Michael E | SVP & General Counsel | Direct | Sell | 2202026 | 204.83 | 1,111 | 227,566 | 7,859,532 | Form |
| 15 | Doherty, Catherine T | EVP, Regional Businesses | Direct | Sell | 2202026 | 204.83 | 1,433 | 293,521 | 14,010,782 | Form |
| 16 | Doherty, Catherine T | EVP, Regional Businesses | Direct | Sell | 2172026 | 206.15 | 26,165 | 5,393,815 | 14,031,958 | Form |
| 17 | Plewman, Patrick | SVP for Diagnostic Services | Direct | Sell | 2122026 | 204.00 | 5,662 | 1,155,048 | 3,137,724 | Form |
| 18 | Davis, J. E | CEO and President | Direct | Sell | 11282025 | 192.22 | 55,093 | 10,589,760 | 23,158,192 | Form |
| 19 | Gregg, Vicky B | Direct | Sell | 11282025 | 191.76 | 1,250 | 239,700 | 3,267,015 | Form | |
| 20 | Delaney, Mark E | SVP & Chief Commercial Officer | Direct | Sell | 11202025 | 187.35 | 7,946 | 1,488,683 | 1,410,746 | Form |
| 21 | Pfeiffer, Gary M | Direct | Sell | 10242025 | 182.40 | 1,482 | 270,317 | 5,368,214 | Form | |
| 22 | Prevoznik, Michael E | SVP & General Counsel | Direct | Sell | 9302025 | 188.13 | 227 | 42,706 | 7,171,035 | Form |
| 23 | Prevoznik, Michael E | SVP & General Counsel | Direct | Sell | 9252025 | 187.02 | 175 | 32,729 | 7,128,756 | Form |
| 24 | Prevoznik, Michael E | SVP & General Counsel | Direct | Sell | 9252025 | 187.12 | 28,288 | 5,293,313 | 7,132,537 | Form |
Investor Activity (13F)
Updated Sep 2, 2026Active managers (13F portfolio over $250M, at least 3 holdings) with a position over $5M that is either over 10% of their portfolio or held in a concentrated book of 50 or fewer total positions. Index/ETF, sovereign, bank, community-bank and charitable/donor-advised filers are excluded.
| Active Manager |
|---|
Quest Diagnostics — Investor Video Playlist
Industry Resources
| Health Care Resources |
| U.S. National Library of Medicine |
| ClinicalTrials.gov |
| Modern Healthcare |
| Healthcare Dive |
| Fierce Healthcare |
| Health Affairs |
| Health Data Management |
| FDA Tracker |
| Health Care Services Resources |
| HealthLeaders Media |
| Medical Economics |
| Physicians Practice |
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.